Open Access

CASE REPORT

Hypofractionated radiotherapy with concomitant sunitinib – is there a radiosensitizing effect?

Daniel Taussky¹, Denis Soulières²

1 Department of Radiation Oncology, CRCHUM - Centre Hospitalier de l’Université de Montréal – Hôpital Notre-Dame, Montreal, Quebec, Canada
2 Department of Medical Oncology, Centre Hospitalier de l’Université de Montréal – Hôpital Notre-Dame, Montreal, Quebec, Canada
Address correspondence to Dr. Daniel Taussky,Centre Hospitalier de l’Université de Montréal – Hôpital NotreDame, Department of Radiation Oncology, 1560 Sherbrooke St. E., Montreal, Quebec H2L 4M1 Canada

Canadian Journal of Urology 2009, 16(2), 4599-4600.

Abstract

We present a case of a patient with metastatic renal cell cancer (RCC) treated with hypofractionated radiotherapy while being treated with sunitinib. He received a single dose of 8 Gy of external beam radiation to a metastatic mass of several centimeters diameter in the right lateral ribs, followed by a second identical dose. Clinically, the patient achieved a nearly complete disappearance of the mass. We discuss the possible synergy between tyrosine kinase receptor inhibitors (TKRIs) and radiotherapy and the importance of dose fractionation.

---

Keywords

---